NCT06357741 Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
| NCT ID | NCT06357741 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Condition | Knee Osteoarthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2021-08-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2021-08-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
Eligibility Criteria
Inclusion Criteria: * patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" . * no drug contraindications . * aged between 45 and 75 . * committed to follow the research procedures, And cooperate with the •implementation of the whole process study . * the patient understands the relevant treatment process . * the patient has the ability to give informed consent . * The patient had not recently taken any medication that affected observation. * the subjects must meet all the inclusion criteria to be eligible to participate in the study . Exclusion Criteria: * mental illness . * patients with malignant tumors. * patients with other infectious diseases . * patients with metabolic bone disease, diabetes and hyperthyroidism. * patients who cannot actively cooperate in the treatment. * hypocalcemia.
Contact & Investigator
Tian Hongtao, Doctorate
PRINCIPAL INVESTIGATOR
Wuhan Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06357741 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06357741 currently recruiting?
Yes, NCT06357741 is actively recruiting participants. Contact the research team at tianhongtao@vip.163.com for enrollment information.
Where is the NCT06357741 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06357741 clinical trial?
NCT06357741 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The principal investigator is Tian Hongtao, Doctorate at Wuhan Union Medical College Hospital. The trial plans to enroll 30 participants.